#Germany #Biomaterials #AMSilk #Neuried #silk proteins

AMSilk Secures EUR 52 Million Strategic Financing to Accelerate Commercial Growth

AMSilk GmbH, a leader in advanced biomaterials derived from silk-based proteins, has announced a significant achievement in its funding journey. The company has secured EUR 52 million in strategic financing, which will play a crucial role in enhancing its production capacity and supporting its growth objectives.

The funding round was spearheaded by existing investor ATHOS (AT Newtec), along with notable contributions from fellow investors MIG Capital and Novo Holdings. This infusion of capital comprises EUR 30 million in cash and EUR 22 million in convertible equity. Such backing underscores investor confidence in AMSilk’s innovative technology and its potential impact on the market.

According to Ralph Fraundorfer, Chief Financial Officer of AMSilk, this support is particularly meaningful in light of the current climate of funding challenges, showcasing the strong belief stakeholders have in the company's ability to execute its scalable technology and establish a robust partner network. AMSilk plans to utilize these funds primarily to bolster its industrial production capabilities, addressing growing global demand for its silk-based protein materials.

In a bid to solidify its position, AMSilk has forged several multi-year production agreements with key industrial partners, ensuring reliable supply and consistent quality across its product offerings. This strategic move is expected to enable the company to transition smoothly into full-scale industrial production, thereby proving its capability to meet the needs of a diversifying market.

Dr. Wolfgang Colberg, Chairman of AMSilk’s Advisory Board, expressed enthusiasm regarding the feedback from consumers, highlighting the increasing interest in their products. The recent funding will empower AMSilk to collaborate closely with its partners and significantly scale up production. Such advancements are pivotal in aspiring to create a transformative industry dedicated to high-performance biotech materials with extensive applications.

With biomanufacturing at its core, AMSilk’s technology reprograms microorganisms to produce silk proteins that are processed into various forms like powders, hydrogels, fibers, and coatings. These biomaterials are inherently sustainable, being 100% protein-based, fully biodegradable, and devoid of microplastics. They find applications in diverse industries, including fashion and automotive, and serve as functional ingredients in the consumer care sector.

Since the successful expansion of its Series C financing in 2023, AMSilk has steadily strengthened its market presence through partnerships with leading global brands across multiple sectors. The collaboration with industry giants such as Evonik and Ajinomoto is pivotal, as these firms facilitate production scalability of its silk proteins. Such alliances are crucial as AMSilk gears up for full industrialization, setting the stage for extensive market readiness.

About AMSilk

AMSilk is at the forefront of advanced biomaterials, specializing in those made from silk proteins. Through a patented technology platform safeguarded by a robust patent portfolio, AMSilk is innovating in the bio-based materials landscape.

By transforming human-made proteins into various formulations, including fibers, yarns, hydrogels, and silk powder, AMSilk delivers high-performance materials that cater to a myriad of applications in industries like textiles, home care, biomedical, and automotive, thus bringing revolutionary benefits to both products and consumers.

The company is committed to continuing its collaborative efforts with global enterprises to forge a path for meaningful change through groundbreaking biotech materials.

For more updates, visit AMSilk's official website or connect with them on LinkedIn.